Skip to main content
GutCited

Galactooligosaccharides (GOS) per Irritable Bowel Syndrome (IBS)

B

Reduces IBS symptoms (pain, bloating, flatulence) in dose-dependent manner. 3.5 g/day showed better results than 7 g/day (excess fermentation at higher dose).

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dgalactooligosaccharides\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

In sintesi

Reduces IBS symptoms (pain, bloating, flatulence) in dose-dependent manner. 3.5 g/day showed better results than 7 g/day (excess fermentation at higher dose).

Key Study Findings

Review
Interplay of probiotics, prebiotics, synbiotics and postbiotics: a review of their therapeutic potential for gastrointestinal …
Dose: None vs: None Outcome: None Effetto: None None

Popolazione: review of prebiotics, probiotics, synbiotics, postbiotics for gastrointestinal inflammation

Randomized Controlled Trial n=45 12 weeks Double-blind
All FODMAPs Aren't Created Equal: Results of a Randomized Reintroduction Trial in Patients With Irritable …
Dose: None vs: Sequential FODMAP subgroup reintroduction Outcome: Abdominal pain and bloating severity Effetto: None p=0.007 fructans; p=0.04 GOS

Popolazione: IBS patients (Rome IV) who improved on FODMAP diet

Randomized Controlled Trial 4 weeks Double-blind
Is a Simplified, Less Restrictive Low FODMAP Diet Possible? Results From a Double-Blind, Pilot Randomized …
Dose: None vs: Traditional low FODMAP diet Outcome: IBS symptom response Effetto: None None

Popolazione: IBS-D patients (Rome IV)

Systematic Review
Nutritional Interventions in Adult Patients With Irritable Bowel Syndrome: An Umbrella Review of Systematic Reviews …
Dose: None vs: Various Outcome: IBS symptom improvement Effetto: Probiotics abdominal pain RR 4.04 (2.36-6.92) None

Popolazione: Adult IBS patients

Randomized Controlled Trial n=34 8 weeks Single-blind
A randomized trial of inulin for bowel symptoms, depression and quality of life in constipation …
Dose: 9.2 g/day total (4.6 g twice daily) vs: Maltodextrin 9.2 g/day placebo Outcome: IBS-SSS score and IBS-QoL score Effetto: IBS-SSS: 267.3→195.8; IBS-QoL: 61.0→77.4 0.026 (IBS-SSS); 0.006 (QoL)

Popolazione: Adults with constipation-predominant IBS

Other
Biotechnological Tools for the Production of Low-FODMAP Wholegrain Wheat and Rye Cookies and Crackers.
Dose: None vs: Standard wholegrain flour products Outcome: FODMAP content reduction in cookies and crackers Effetto: Up to 99.5% FODMAP reduction (wheat malt) None

Popolazione: Laboratory food science study (no human subjects)

Key Statistics

3

Studi

400

Partecipanti

Positive

B

Grado

Referenced Papers

Foods (Basel, Switzerland) 2025 3 citazioni
Archivos argentinos de … 2024 3 citazioni
Frontline gastroenterology 2021 56 citazioni
Critical reviews in … 2019 35 citazioni
Foods (Basel, Switzerland) 2019 21 citazioni
The American journal … 2019 15 citazioni
Journal of gastroenterology … 2017 181 citazioni
International journal of … 2017 146 citazioni
Journal of gastroenterology … 2017 32 citazioni
Current opinion in … 2017 24 citazioni
World journal of … 2016 238 citazioni
Scandinavian journal of … 2016 17 citazioni
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2016 2 citazioni
Journal of neurogastroenterology … 2015 60 citazioni
Menopause international 2009 29 citazioni
Alimentary pharmacology & … 2006 629 citazioni
The British journal … 2001 166 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
2.5-5 g/day
ibssupport:
3.5 g/day (optimal dose; higher doses may increase symptoms)
infantgutsupport:
0.24-0.48 g/100 mL formula (added to infant formula)

Limite massimo: Well-tolerated up to 15 g/day; optimal dose appears to be 3.5-5 g/day

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
None -- Positive --
None 12 weeks Negative 45
None 4 weeks Mixed --
None -- Positive --
9.2 g/day total (4.6 g twice daily) 8 weeks Positive 34
None -- Positive --
1e9 CFU/day + GOS 10 g/L -- Positive --
None -- Neutral --

Momento migliore per l'assunzione: With meals; start with lower dose and increase gradually

Safety & Side Effects

Effetti collaterali segnalati

  • Gas and bloating (especially above 5 g/day; dose-response is U-shaped)
  • Flatulence at higher doses
  • Abdominal cramping if dose increased too quickly
  • May worsen symptoms in FODMAP-sensitive individuals

Interazioni note

  • Other FODMAPs (cumulative fermentation in sensitive individuals)
  • Lactose-containing products (GOS is derived from lactose; generally safe for lactose-intolerant individuals as GOS itself is lactose-free)

Livello di assunzione massimo tollerabile: Well-tolerated up to 15 g/day; optimal dose appears to be 3.5-5 g/day

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Galactooligosaccharides (GOS) help with Irritable Bowel Syndrome (IBS)?
Based on 3 studies with 400 participants, there is moderate evidence from clinical studies that Galactooligosaccharides (GOS) may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Galactooligosaccharides (GOS) should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 2.5-5 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Galactooligosaccharides (GOS)?
Reported side effects may include Gas and bloating (especially above 5 g/day; dose-response is U-shaped), Flatulence at higher doses, Abdominal cramping if dose increased too quickly, May worsen symptoms in FODMAP-sensitive individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Galactooligosaccharides (GOS) and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 400 total participants. The overall direction of effect is positive.

Related Evidence

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.